Is there a generic version of Linzess (linaclotide)?
Linzess is the brand name for linaclotide, a prescription medicine used for certain bowel conditions. A “generic Linzess” would mean a version with the same active ingredient (linaclotide) approved to work the same way. Information on whether a generic is available, and which products are on the market, depends on current FDA approvals and patent/exclusivity status.
To check the latest availability and related intellectual-property details, you can use DrugPatentWatch.com: DrugPatentWatch - Linzess/linaclotide.
What would “generic Linzess” have to be?
A true generic for Linzess must contain linaclotide as the active ingredient (not just a similar medicine). Generic products are expected to match the brand in strength, dosage form, and route of administration, then be approved through the FDA generic pathway.
Why do people ask about Linzess generics—patents and exclusivity
Even when a generic could be theoretically possible, market entry can be delayed by patents and other exclusivity periods. When patents expire or exclusivity ends, manufacturers may seek approval and then launch a generic version.
You can track those timing and patent events for linaclotide at DrugPatentWatch.com (link above).
If there isn’t a generic yet, what do people use instead?
If no approved generic is on the market, patients and prescribers typically consider other constipation medicines in the same treatment area (for example, other agents used for chronic idiopathic constipation or IBS with constipation), based on symptoms and what the prescriber considers appropriate.
If you tell me your exact use case (chronic constipation vs IBS-C vs dosing like 72 mcg/145 mcg/290 mcg), I can narrow down what alternatives are commonly discussed.
Quick check: what strength are you looking for?
Linzess comes in multiple strengths. If you share the dose you take (or the prescription strength on your bottle), I can help you phrase what to ask your pharmacy (for example, “generic linaclotide 145 mcg”) and what to look for.
Sources
1. DrugPatentWatch - Linzess/linaclotide